European Primary Care Cardiovascular Society

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Pharmacist intervention in American 'black barbershops' effective at lowering BP

Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France

Striking results for weight reduction in T2DM in primary care based program

Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

Nov. 20, 2017 - AHA 2017 - Anaheim, CA, USA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

Good BP measurement depends more on appropriate technique than on absence of staff

Nov. 25, 2017 - AHA 2017 - Anaheim, CA, USA - Prof Karen Johnson - Memphis, TN, VS

Things to consider when aiming to prevent stroke in a patient with AF

May 25, 2017
##SCROLLER_ITEMS_FULL_TITLE##

What can be learned from the latest hypertension trials?

May 26, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management varies substantially across European countries

May 25, 2017

How do the latest guideline changes affect management of dyslipidaemia in primary care?

May 26, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Ingredients of effective strategies to stimulate behaviour change

May 25, 2017

The evidence base for health behaviour changes

Dec. 9, 2015 - EPCCS 2015 - Prague, Czech Republic

Identifying and treating patients with true hypertension

Feb. 24, 2016 - Prague - EPCCS 2015

What is the evidence base for lipid modification in the guidelines updates?

Feb. 24, 2016 - Prague - EPCCS 2015
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management

Dec. 9, 2015 - EPCCS 2015 - Prague

​Stroke prevention in atrial fibrillation

Mar. 12, 2014 - Amsterdam - Hobbs, Rutten

The EPCCS Stroke Prevention in Atrial Fibrillation Guidance Document 1

Jan. 7, 2014 - EPCCS 2014, Brussels - Prof. David Fitzmaurice

What's the evidence for BP and lipid targets in diabetes?

Nov. 25, 2014 - EPCCS 2014, Brussels

Debate: should we treat lifetime risk or 10-year risk?

Nov. 25, 2014 - Brussels, Belgium - Prof R. Hobbs, Th. Christiaens, C.Brotons & A. Hoes - EPCCS 2014

Alcohol as a risk factor for hypertension

Nov. 20, 2014 - Brussels, Belgium - Prof. Daniel Duprez (Minnesota, USA) - EPCCS 2014

Fasting during Ramadan with HFrEF is safe, if patients adhere to diet and meds

Apr. 17, 2018 - news

Ramadan starts on May 16. A study found that religious fasting is safe for patients with HFrEF, but non-adherence to medication and diet increases the risk of decompensated HF.

Various types of CVD events are differently affected by alcohol consumption

Apr. 16, 2018 - Wood AM et al., - The Lancet 2018

In a large prospective study, risk of all-cause mortality increases above 100 g alcohol per week, and positive associations with alcohol intake were seen mostly for stroke and HF, as opposed to MI.

Variability of lipid levels is predictive of CV events

Apr. 12, 2018 - Waters DD, et al. - J Clin Lipidol 2018

Visit-to-visit variability in fasting measurements of HDL-c, TG, and LDL-c is predictive of coronary events, CV events, and TG and LDL-c variability is also predictive of incident diabetes.

Complexities of managing heart failure in primary care

Dr. Nuria Farré - Barcelona, Spain and dr. Miguel Angel Muñoz - Barcelona, Spain

EPCCS 2018 An impression of the presentations of dr. Nuria Farré and dr. Miguel Angel Muñoz on the diagnosis and monitoring of heart failure, co-morbidities, palliative care and the evidence on these topics given during the Annual EPCCS CV Summit.

Hypertension – can we agree on diagnostic and therapeutic thresholds?

Prof. Richard McManus - Oxford, UK

EPCCS 2018 An impression of the presentation of Prof. Richard McManus on the evidence of thresholds, the difference in guidelines and the role of the GP, given during the Annual EPCCS CV Summit.

Statins are underutilized in peripheral artery disease patients

Apr. 10, 2018 - Arya S et al. - Circulation. 2018

In a large community-based database, in patients with peripheral artery disease, statin therapy was associated with a significant reduction of amputations and mortality compared with no statin use.

Managing elevated lipids and statins – the good, the bad and the ugly?

Prof. Frank Visseren - UMC Utrecht, The Netherlands

EPCCS 2018 An impression of the presentation of Prof. Frank Visseren on the evidence, the guidelines and the clinical reality of lipid-lowering therapies, given during the Annual EPCCS CV Summit.

When diastolic BP falls below 55 mmHg, the risk of CV events increased

Apr. 3, 2018 - Khan NA et al. - Hypertension. 2018

In the SPRINT study, a diastolic threshold of <55 mmHg was associated with increased cardiovascular events in both patients with and without cardiovascular disease.

Atrial fibrillation poses people at higher risk of dementia

Mar. 29, 2018 - Chen LY et al. - J Am Heart Assoc. 2018

Incident atrial fibrillation (AF) is associated with both greater cognitive decline and increased risk of dementia compared with individuals without AF, independent of clinical ischemic stroke.

Diabetes and vascular disease: epidemiology and management options

Dr. Xavier Cos - Barcelona, Spain

EPCCS 2018 An impression of the presentation of dr. Xavier Cos on diabetes and vascular disease, epidemiology and management options, given during the Annual EPCCS CV Summit.

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA
Dr. Valentin Fuster explains why he thinks that the ODYSSEY OUTCOMES results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

Pharmacist intervention in American 'black barbershops' effective at lowering BP

Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA
Barbershops and pharmacists worked together in Los Angeles County, to improve high BP in non-hispanic black men, a group with particularly high rates of uncontrolled hypertension. In a randomized design, a pharmacist intervention led to 27 mmHg drop over 6 months, vs. 9 mmHg in controls.

ACC 2018 Black barbershops and pharmacists worked together to improve high BP in non-hispanic black men. In a randomized design, a pharmacist intervention led to 27 mmHg drop in SBP over 6 months, vs. 9 mmHg in controls.